Spinocerebellar ataxia type 7 (SCA7) is a dominantly inherited, progressive neurodegenerative disease, which falls in a family of disorders caused by an expanded CAG repeat within the gene’s protein-coding region. This type of mutation produces an abnormal poly-glutamine tract within the diseased protein, leading to errors in folding and the formation of characteristic intracellular aggregates. SCA7 results in neurodegeneration within the hindbrain as well as photoreceptor degeneration in the retina, resulting in a loss of motor coordination and vision. To further characterize SCA7 pathogenesis, this study investigated the possibility of disease reversibility using a SCA7 murine model. At 24 weeks, cre-mediated recombination was induced to excise the mutant gene, effectively ceasing mutant gene expression in animals. Prior to and following gene excision, animals were observed for phenotypic changes in gait, spine curvature, hind limb clasping, ability to walk on a cage ledge, and performance on a Rotarod test. All animals were followed through 44 weeks of age, or the average lifespan of SCA7 mice. Following gene excision, SCA7 animals improved in all measured parameters of motor coordination, showing some reversal of disease pathology. Utilizing immunohistochemistry techniques, cerebellar sections from mice (aged 43-44 weeks) were analyzed for the pathology of Purkinje cell dendrites and Bergmann glia processes, two cerebellar cell types previously found to be significantly affected in ataxic animals. When compared with untreated SCA7 mice, there was a decrease in the degree of degeneration in both cell types of SCA7 animals that underwent gene excision treatment. These results suggest that continued expression of the mutant gene is necessary for SCA7 pathology to progress and that treatment, even after the onset of disease symptoms, may have the potential to ameliorate the disease phenotype.